- Home
- HBM vs AXSM Comparison
HBM vs AXSM Comparison
Compare HBM & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBM
- AXSM
- Stock Information
- Founded
- HBM 1927
- AXSM 2012
- Country
- HBM Canada
- AXSM United States
- Employees
- HBM N/A
- AXSM N/A
- Industry
- HBM Metal Mining
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- HBM Basic Materials
- AXSM Health Care
- Exchange
- HBM Nasdaq
- AXSM Nasdaq
- Market Cap
- HBM 4.6B
- AXSM 5.1B
- IPO Year
- HBM N/A
- AXSM 2015
- Fundamental
- Price
- HBM $11.97
- AXSM $121.28
- Analyst Decision
- HBM
- AXSM Strong Buy
- Analyst Count
- HBM 0
- AXSM 16
- Target Price
- HBM N/A
- AXSM $176.56
- AVG Volume (30 Days)
- HBM 6.7M
- AXSM 553.1K
- Earning Date
- HBM 08-13-2025
- AXSM 08-04-2025
- Dividend Yield
- HBM 0.14%
- AXSM N/A
- EPS Growth
- HBM 216.33
- AXSM N/A
- EPS
- HBM 0.72
- AXSM N/A
- Revenue
- HBM $2,202,000,000.00
- AXSM $495,033,000.00
- Revenue This Year
- HBM $13.55
- AXSM $64.05
- Revenue Next Year
- HBM N/A
- AXSM $56.46
- P/E Ratio
- HBM $16.54
- AXSM N/A
- Revenue Growth
- HBM 8.31
- AXSM 69.83
- 52 Week Low
- HBM $5.95
- AXSM $75.56
- 52 Week High
- HBM $12.10
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- HBM 69.03
- AXSM 70.77
- Support Level
- HBM $11.48
- AXSM $115.99
- Resistance Level
- HBM $11.82
- AXSM $123.59
- Average True Range (ATR)
- HBM 0.35
- AXSM 3.29
- MACD
- HBM 0.12
- AXSM 1.24
- Stochastic Oscillator
- HBM 90.12
- AXSM 88.56
About HBM Hudbay Minerals Inc. (Canada)
Hudbay Minerals Inc is a Canadian mining company with its operations, property developments, and exploration activities across the United States. The mines that Hudbay operates are located in Manitoba, Canada, Arizona, United States; and Peru. The company is principally focused on the discovery, production, and marketing of base and precious metals. Hudbay produces copper concentrate, which contains copper, gold, and silver, as well as zinc metal. More than half the company's revenue is attributable to the copper business. The company sells copper concentrates to smelters across Asia, America, and Europe, and sells Zinc metal, another source of revenue, to industrial customers across North America.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.